1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19545
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZanchetti, A.en
dc.contributor.authorJulius, S.en
dc.contributor.authorKjeldsen, S.en
dc.contributor.authorMcInnes, G. T.en
dc.contributor.authorHua, T.en
dc.contributor.authorWeber, M.en
dc.contributor.authorLaragh, J. H.en
dc.contributor.authorPlat, F.en
dc.contributor.authorBattegay, E.en
dc.contributor.authorCalvo-Vargas, C.en
dc.contributor.authorCieslinski, A.en
dc.contributor.authorDegaute, J. P.en
dc.contributor.authorHolwerda, N. J.en
dc.contributor.authorKobalava, J.en
dc.contributor.authorPedersen, O. L.en
dc.contributor.authorRudyatmoko, F. P.en
dc.contributor.authorSiamopoulos, K. C.en
dc.contributor.authorStorset, O.en
dc.date.accessioned2015-11-24T19:00:30Z-
dc.date.available2015-11-24T19:00:30Z-
dc.identifier.issn0263-6352-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19545-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAmlodipine/*therapeutic useen
dc.subjectAngiotensin II Type 1 Receptor Blockers/*therapeutic useen
dc.subjectCalcium Channel Blockers/*therapeutic useen
dc.subjectFemaleen
dc.subjectHeart Arrest/mortality/*prevention & controlen
dc.subjectHeart Failure/mortality/*prevention & controlen
dc.subjectHumansen
dc.subjectHypertension/complications/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProportional Hazards Modelsen
dc.subjectSex Factorsen
dc.subjectTetrazoles/*therapeutic useen
dc.subjectTreatment Outcomeen
dc.subjectValine/*analogs & derivatives/therapeutic useen
dc.titleOutcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trialen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1097/01.hjh.0000249692.96488.46-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17053536-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractBACKGROUND: In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) and diastolic blood pressure reductions were significantly more pronounced with amlodipine. Stroke incidence was non-significantly, and myocardial infarction was significantly lower in the amlodipine-based regimen, whereas cardiac failure was non-significantly lower on valsartan. OBJECTIVES: The study protocol specified additional analyses of the primary endpoint according to: sex; age; race; geographical region; smoking status; type 2 diabetes; total cholesterol; left ventricular hypertrophy; proteinuria; serum creatinine; a history of coronary heart disease; a history of stroke or transient ischemic attack; and a history of peripheral artery disease. Additional subgroups were isolated systolic hypertension and classes of antihypertensive agents used immediately before randomization. METHODS: The 15,245 hypertensive patients participating in VALUE were divided into subgroups according to baseline characteristics. Treatment by subgroup interaction analyses were carried out by a Cox proportional hazard model. Within each subgroup, treatment effects were assessed by hazard ratios and 95% confidence intervals. RESULTS: For cardiac mortality and morbidity, the only significant subgroup by treatment interaction was of sex (P = 0.016), with the hazard ratio indicating a relative excess of cardiac events with valsartan treatment in women but not in men, but SBP differences in favour of amlodipine were distinctly greater in women. No other subgroup showed a significant difference in the composite cardiac outcome between valsartan and amlodipine-based treatments. For secondary endpoints, a sex-related significant interaction was found for heart failure (P < 0.0001), with men but not women having a lower incidence of heart failure with valsartan. CONCLUSION: As in the whole VALUE cohort, in no subgroup of patients were there differences in the incidence of the composite cardiac endpoint with valsartan and amlodipine-based treatments, despite a greater blood pressure decrease in the amlodipine group. The only exception was sex, in which the amlodipine-based regimen was more effective than valsartan in women, but not in men, whereas the valsartan regimen was more effective in preventing cardiac failure in men than in women.en
heal.journalNameJournal of Hypertensionen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons